A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

Inclusion Criteria: * Patients with clinical history of intermittent allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each of the last two ragweed allergy seasons * positive skin prick test to ragweed allergen within twelve months of screening Exclusion criteria: * Use of any medication used to treat allergy (administered via any route), such as: pseudoephedrine, antihistamines, ipratropium bromide, cromoglycates, corticosteroids, immunotherapy or other antiinflammatory or immunosuppressive agents, or any other medication administered via the nasal or ocular routes) * Within the last three years a recurrent history of acute or chronic bronchospastic disease including moderate-severe asthma or chronic obstructive pulmonary disease * Nasal conditions such as nasal septal perforations,nasal polyps, sinus disease, chronic nasal obstruction Other protocol-defined inclusion/exclusion criteria may apply